Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Ovid Therapeutics Stock Is Imploding Today

By Prosper Junior Bakiny - Dec 2, 2020 at 11:38AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported disappointing results from a late-stage clinical trial.

What happened?

Shares of Ovid Therapeutics ( OVID -0.93% ) -- a clinical-stage biotech company -- are down by 55% as of 11:04 a.m. EST on Wednesday, after falling by as much as 56.4% earlier in the day. Investors are selling off shares of the drugmaker following negative results from a pivotal phase 3 clinical trial for one of its leading pipeline candidates, OV101.

So what

Ovid Therapeutics focuses on developing treatments for neurological diseases, and the company was investigating OV101 as a potential medicine for Angelman syndrome. This rare genetic disorder is typically diagnosed in children and causes delayed development, sleep disorders, speech impairment, and seizures, among other things. In a phase 3 clinical trial, Ovid Therapeutics enrolled 104 patients between the ages of 2 and 12 and treated them with either OV101 or a placebo for 12 weeks.

Road sign that says "risk ahead."

Image source: Getty Images.

The goal was to assess the effects of OV101 on patients diagnosed with Angelman syndrome. The primary endpoint of the trial was "change in overall score on the Clinical Global Impression-Improvement-Angelman syndrome (CGI-I-AS) scale." Unfortunately, OV101 failed to meet its primary endpoint during the trial. Patients treated with the drug achieved a 0.7 point improvement on the CGI-I-AS scale, while those treated with placebo achieved a 0.8 point improvement on the scale.

Now what

There is no standard of care and no drug approved by the U.S. Food and Drug Administration (FDA) for Angelman syndrome. And while there remains a dire need for a drug for this condition, it doesn't look as though OV101 will go on to earn regulatory approval, given the results of this clinical trial. That doesn't bode well for Ovid Therapeutics, and it explains why shares of the biotech company -- which has no drugs on the market at the moment -- are getting clobbered on the stock market today. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ovid Therapeutics Inc. Stock Quote
Ovid Therapeutics Inc.
OVID
$3.21 (-0.93%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
640%
 
S&P 500 Returns
139%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.